Grifols (NASDAQ:GRFS) Hits New 1-Year Low – Time to Sell?

Grifols, S.A. (NASDAQ:GRFS) shares hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $7.07 and last traded at $7.0730, with a volume of 555410 shares changing hands. The stock had previously closed at $7.33.

Wall Street Analysts Forecast Growth

GRFS has been the subject of several research analyst reports. Weiss Ratings lowered shares of Grifols from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. Wall Street Zen cut shares of Grifols from a “buy” rating to a “hold” rating in a report on Monday, May 18th. Finally, Zacks Research lowered shares of Grifols from a “hold” rating to a “strong sell” rating in a report on Friday, May 8th. Two investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Reduce” and an average target price of $10.00.

Grifols Stock Down 3.1%

The firm has a market cap of $4.84 billion, a P/E ratio of 37.39, a price-to-earnings-growth ratio of 0.29 and a beta of 0.65. The stock’s 50 day simple moving average is $7.80 and its 200 day simple moving average is $8.45. The company has a debt-to-equity ratio of 1.16, a quick ratio of 0.85 and a current ratio of 2.47.

Grifols (NASDAQ:GRFS) last released its quarterly earnings data on Saturday, February 14th. The biotechnology company reported $0.38 earnings per share for the quarter. The firm had revenue of $2.32 billion for the quarter. Grifols had a net margin of 5.54% and a return on equity of 6.21%. Research analysts anticipate that Grifols, S.A. will post 1.06 EPS for the current year.

Grifols Dividend Announcement

The business also recently declared a special dividend, which will be paid on Thursday, July 9th. Shareholders of record on Thursday, July 2nd will be paid a dividend of $0.0945 per share. The ex-dividend date is Thursday, July 2nd. Grifols’s payout ratio is 73.68%.

Institutional Trading of Grifols

Several institutional investors and hedge funds have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Grifols by 25.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,928 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 1,212 shares during the last quarter. PNC Financial Services Group Inc. raised its position in Grifols by 50.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 8,961 shares of the biotechnology company’s stock valued at $72,000 after buying an additional 2,998 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in Grifols by 127.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company’s stock valued at $74,000 after acquiring an additional 4,604 shares in the last quarter. Allworth Financial LP boosted its holdings in Grifols by 15.7% during the 4th quarter. Allworth Financial LP now owns 8,073 shares of the biotechnology company’s stock worth $75,000 after acquiring an additional 1,096 shares during the last quarter. Finally, Ameriprise Financial Inc. purchased a new stake in shares of Grifols in the second quarter valued at about $95,000.

Grifols Company Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.